Glycopeptide antibiotics work by physically binding to the building blocks of bacterial cell walls, preventing bacteria from assembling the rigid outer structure they need to survive. Vancomycin, the most widely used member of the class, has been a cornerstone treatment for serious drug-resistant infections since the 1950s, and it remains one of the go-to drugs for methicillin-resistant Staphylococcus aureus (MRSA). But the class is broader than vancomycin alone, and the story of how these drugs work, where they fall short, and what happens when bacteria learn to resist them is more layered than a simple “antibiotic kills bacteria” summary suggests.
How Glycopeptides Kill Bacteria
Bacteria build their cell walls from a mesh-like material called peptidoglycan. The final step in assembling that mesh requires linking together precursor molecules that end in a specific two-amino-acid sequence: D-alanyl-D-alanine (often written D-Ala-D-Ala). Glycopeptide antibiotics latch onto that D-Ala-D-Ala tail through hydrogen bonds, essentially capping the precursor so the bacterial enzymes responsible for cross-linking the wall can no longer do their job.1PubMed Central. In vivo studies suggest that induction of VanS-dependent vancomycin resistance requires binding of the drug to D-Ala-D-Ala termini in the peptidoglycan cell wall Without cross-linking, the growing wall is structurally weak. As the bacterium tries to divide, it essentially bursts under its own internal pressure.
This target is what makes glycopeptides distinctive compared to other antibiotics that also attack the cell wall, like penicillins. Penicillins inhibit the enzymes that do the cross-linking. Glycopeptides instead grab onto the raw material those enzymes need. The two approaches can complement each other, which becomes clinically relevant when doctors combine them against tough infections.
Why They Only Work Against Gram-Positive Bacteria
Glycopeptides are large molecules, and that size is their main limitation. Gram-negative bacteria have an additional outer membrane surrounding their cell wall that acts as a barrier. Vancomycin simply cannot get through it.2PubMed Central. Vancomycin-Polyguanidino Dendrimer Conjugates Inhibit Growth of Antibiotic-Resistant Gram-Positive and Gram-Negative Bacteria and Eradicate Biofilm-Associated S. aureus Gram-positive bacteria lack this outer membrane, leaving their peptidoglycan-rich wall exposed and accessible.3PubMed Central. Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli
This means glycopeptides are primarily weapons against organisms like Staphylococcus aureus (including MRSA), Enterococcus species, Streptococcus species, and Clostridioides difficile. They have essentially no role in treating infections caused by gram-negative organisms like E. coli or Pseudomonas, unless researchers find creative ways to breach that outer membrane.
Main Clinical Uses
The headline indication for intravenous vancomycin is serious MRSA infection. Bloodstream infections, bone and joint infections, endocarditis, and hospital-acquired pneumonia caused by MRSA are all scenarios where vancomycin is a first-line choice. Consensus guidelines from multiple infectious-disease societies recommend targeting a specific drug-exposure ratio to balance effectiveness against toxicity in these serious infections.4American Journal of Health-System Pharmacy. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review In emergency settings, vancomycin is widely prescribed once MRSA is suspected: a single-center study of ED patients with MRSA bloodstream infections found that roughly two-thirds received intravenous vancomycin in the emergency department itself.5JACEP Open. Methicillin-resistant Staphylococcus aureus and Vancomycin Prescribing in the Emergency Department: A Single-center Study Assessing Antibiotic Prescribing
Teicoplanin, the other “classic” glycopeptide, is used for similar gram-positive infections in many countries outside the United States, where it is not FDA-approved. It shares the same fundamental mechanism but has a longer half-life and a different side-effect profile, which we will return to.
Oral Vancomycin for C. difficile Infection
In a twist that confuses many patients, vancomycin can also be given by mouth, but the goal is completely different. Oral vancomycin is a primary treatment for C. difficile colitis, the severe diarrheal infection that often follows antibiotic use. When swallowed, vancomycin stays in the gut and is barely absorbed into the bloodstream. A study of 57 patients receiving oral vancomycin at standard doses found no detectable drug in the blood of all but one patient, who had only a brief, transient level.6PubMed. Systemic absorption of oral vancomycin in patients with Clostridium difficile infection
That lack of absorption is actually the point. Because the drug stays in the intestine, it reaches very high concentrations right where C. difficile lives. Patients receiving higher oral doses achieved gut levels more than a thousand times greater than the concentration needed to kill C. difficile.7PubMed Central. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection The downside is that oral vancomycin is useless for any infection outside the gut, and intravenous vancomycin is useless for C. difficile because it does not reach the intestinal lumen in adequate concentrations.
Red Man Syndrome
The most recognizable acute side effect of vancomycin is red man syndrome, an infusion-related reaction that causes flushing, itching, and sometimes a dramatic red rash across the face, neck, and upper body. Despite how alarming it looks, it is not a true allergy. The reaction is driven by direct histamine release from mast cells, and its severity tracks with how fast the drug is infused.8PubMed Central. Vancomycin-induced histamine release and “red man syndrome”: comparison of 1- and 2-hour infusions Slowing the infusion rate to at least one hour, and often two, dramatically reduces the problem. Pretreatment with antihistamines can help as well.
This distinction matters because labeling a patient “vancomycin-allergic” based on red man syndrome alone can cut them off from a drug they may genuinely need. True vancomycin allergy exists but is far less common than infusion-related histamine release.
Kidney Damage
Nephrotoxicity is the side effect clinicians worry about most during prolonged vancomycin courses. The mechanism appears to involve oxidative stress in the kidney’s proximal tubule cells. Animal studies have shown that vancomycin causes destruction of kidney structures including glomeruli and proximal tubules, and that targeting antioxidant enzymes to those cells can reduce the damage.9PubMed. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats This has fueled interest in whether antioxidant co-therapies could someday allow safer use of higher vancomycin doses.10PubMed Central. Review of vancomycin-induced renal toxicity: an update
In practice, the risk of kidney injury rises with higher drug levels, longer treatment courses, and when vancomycin is combined with other kidney-stressing drugs like piperacillin-tazobactam. This is why drug-level monitoring is so central to vancomycin management.
How Vancomycin Levels Are Monitored
For decades, clinicians tracked vancomycin by measuring trough levels, the lowest concentration in the blood just before the next dose. Current guidelines have shifted toward a more precise approach: estimating the total drug exposure over 24 hours (area under the curve, or AUC) relative to the bacteria’s sensitivity. An AUC-to-MIC ratio of 400 to 600 is the recommended target for serious MRSA infections.11PubMed Central. The Safety and Efficacy of AUC/MIC-Guided vs Trough-Guided Vancomycin Monitoring Among Veterans
A meta-analysis confirmed that patients who achieved the higher AUC-to-MIC targets had markedly lower treatment failure rates.12PubMed Central. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing AUC-guided monitoring also appears to get patients into the therapeutic range faster than older trough-based approaches, while potentially reducing kidney injury by avoiding unnecessarily high peaks.11PubMed Central. The Safety and Efficacy of AUC/MIC-Guided vs Trough-Guided Vancomycin Monitoring Among Veterans The practical catch is that AUC-guided dosing requires either two blood draws per dose cycle or Bayesian pharmacokinetic software, which not every hospital has set up.
Teicoplanin as a Safer Alternative
Teicoplanin binds the same D-Ala-D-Ala target but has a structurally different backbone that leads to meaningful clinical differences. A systematic review and meta-analysis comparing the two drugs found that teicoplanin was associated with roughly 40 percent fewer total adverse events, significantly less nephrotoxicity, and a lower rate of red man syndrome, all without sacrificing effectiveness.13PubMed Central. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis Even in combination with other nephrotoxic drugs like piperacillin-tazobactam, the teicoplanin-based regimen showed about half the rate of acute kidney injury compared to vancomycin.14PubMed. Comparative Risk of Acute Kidney Injury with Piperacillin-Tazobactam Plus Teicoplanin Versus Piperacillin-Tazobactam Plus Vancomycin: A Systematic Review and Meta-Analysis
Given these advantages, you might wonder why vancomycin remains dominant. The answer is mostly regulatory and economic. Teicoplanin is unavailable in the U.S., and decades of clinical experience with vancomycin have made it the default. In Europe, Asia, and much of the rest of the world, teicoplanin is a genuine first-line alternative, and many clinicians prefer it for patients at high risk of kidney problems.
How Bacteria Become Resistant
Vancomycin resistance in enterococci, the most clinically common form, happens when bacteria acquire genes (most often the vanA gene cluster) that produce enzymes capable of rebuilding cell wall precursors with a modified ending: D-Ala-D-lactate instead of D-Ala-D-Ala. The enzyme D-alanine-D-lactate ligase directly manufactures these alternate precursors.15PubMed. The molecular basis of vancomycin resistance in clinically relevant Enterococci: crystal structure of D-alanyl-D-lactate ligase (VanA) That single oxygen-for-nitrogen swap at the binding site reduces vancomycin’s grip on its target by about a thousandfold, which is more than enough to make the drug clinically useless.16PubMed Central. A redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria
Staphylococcus aureus uses a different strategy. Rather than remodeling its target, resistant staph strains thicken their cell walls. The extra layers act like a sponge, trapping vancomycin molecules before they reach the inner sites where cross-linking actually occurs. Studies have shown a strong correlation between wall thickness and the level of vancomycin resistance, and when resistant strains are grown without the drug, their walls thin out and susceptibility returns.17PubMed Central. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus Full-blown vancomycin-resistant S. aureus (VRSA), which has acquired the vanA gene cluster from enterococci, remains rare but represents a worst-case scenario that infectious-disease specialists track closely.
Lipoglycopeptides and Single-Dose Therapy
The newest members of the glycopeptide family are lipoglycopeptides: oritavancin, dalbavancin, and telavancin. These drugs were engineered by attaching a lipid side chain to the core glycopeptide structure, which gives them extra tricks. Oritavancin, for instance, not only blocks cell wall synthesis but also disrupts the bacterial cell membrane itself, a second killing mechanism that standard glycopeptides do not have.18Clinical Infectious Diseases. Oritavancin: A Long-Half-Life Lipoglycopeptide
The most striking feature of oritavancin and dalbavancin is their extraordinarily long half-lives. Oritavancin has a terminal half-life of about 393 hours, which allows a single intravenous dose to treat acute bacterial skin and skin-structure infections without any follow-up doses.18Clinical Infectious Diseases. Oritavancin: A Long-Half-Life Lipoglycopeptide Dalbavancin similarly allows infrequent dosing.19PubMed. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin For patients who might otherwise need daily IV infusions for a week or more, or who struggle with follow-up, a one-and-done treatment is a genuine practical breakthrough. These agents are currently approved for skin infections, and clinicians are exploring off-label use for bone and joint infections where prolonged IV courses have traditionally been the only option.
Combining Vancomycin with Beta-Lactams
One of the more interesting developments in vancomycin prescribing is the deliberate pairing of vancomycin with beta-lactam antibiotics against MRSA. This sounds counterintuitive because MRSA is, by definition, resistant to beta-lactams. But the combination works at a pharmacological level rather than expecting the beta-lactam to kill on its own. Lab studies have consistently shown synergistic killing when vancomycin is paired with beta-lactams like cefazolin or nafcillin against strains with various degrees of vancomycin susceptibility, including intermediate-resistant strains.20PubMed Central. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA
Earlier animal experiments demonstrated the same phenomenon in a living system. In a rabbit model of endocarditis caused by glycopeptide-intermediate S. aureus, neither vancomycin nor nafcillin alone was effective, but the combination reduced bacteria in heart valve tissue by more than four orders of magnitude compared to untreated controls.21PubMed. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin The likely explanation is that the beta-lactam weakens the cell wall just enough to let vancomycin reach its target more effectively, even in strains with thickened walls. This strategy is increasingly used in practice for serious MRSA infections, particularly endocarditis and persistent bacteremia.
Rare but Serious Reactions
Beyond nephrotoxicity and red man syndrome, vancomycin can trigger DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), a delayed hypersensitivity reaction that typically appears two to six weeks after treatment starts. Symptoms include a widespread rash, fever, elevated white blood cells (specifically eosinophils), and organ involvement such as liver inflammation. A case report described a patient who developed DRESS after seven weeks of vancomycin treatment for a deep spinal hardware infection.22PubMed Central. Vancomycin-Induced DRESS Syndrome: An Important Concern in Orthopedic Surgery Because the onset is so delayed, DRESS can initially be mistaken for a new infection or sepsis rather than a drug reaction, leading to continued vancomycin exposure at exactly the wrong time.23PubMed Central. Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Masquerading as Elusive Sepsis Treatment involves stopping vancomycin immediately and switching to an alternative like linezolid, usually with corticosteroids to control the immune reaction.
Hearing loss has also been reported with vancomycin, though disentangling it from the effects of other ototoxic drugs given at the same time, particularly aminoglycosides, has proven difficult. Whether the two drug classes produce additive damage to hearing remains unclear.
Dosing Challenges in Newborns and Infants
Vancomycin pharmacokinetics in neonates are wildly variable compared to adults. How quickly a newborn clears the drug depends heavily on kidney maturity, which itself is a function of gestational age, postnatal age, and weight. A population pharmacokinetic study of neonates and infants identified serum creatinine, postmenstrual age, and weight as the key factors influencing vancomycin clearance.24PubMed Central. Predicting Vancomycin Clearance in Neonates and Infants by Integrating Machine Learning and Metabolomics With Population Pharmacokinetics The adult AUC-to-MIC target of 400 to 600 has been adopted as a starting framework for neonatal dosing, but whether it applies to newborns the same way it does to adults is still an open question, and further investigation is needed before treating it as settled.25PubMed Central. Challenges of Vancomycin Dosing and Therapeutic Monitoring in Neonates
This variability means that neonatal dosing is closer to an art than a protocol. Many neonatal intensive care units use pharmacist-driven individualized dosing programs, and researchers are exploring whether machine learning models trained on clinical and even metabolomic data can predict clearance more accurately than standard formulas.
Redesigning Vancomycin to Overcome Resistance
Rather than searching for entirely new drug classes, some researchers have taken vancomycin itself and subtly redesigned its binding pocket to restore activity against resistant bacteria. The central idea is to modify the part of the molecule that contacts D-Ala-D-Ala so that it also binds D-Ala-D-Lac, the altered target that resistant bacteria produce. One such redesigned compound showed binding to the normal D-Ala-D-Ala target that was only about twofold weaker than natural vancomycin, while simultaneously gaining roughly 600-fold stronger binding to the resistant D-Ala-D-Lac target compared to unmodified vancomycin.16PubMed Central. A redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria
This work has been extended into what researchers call “maxamycins,” compounds built through total chemical synthesis that incorporate binding-pocket modifications along with additional structural changes intended to create multiple independent mechanisms of action. The rationale is that bacteria would need to simultaneously develop resistance to all of the drug’s killing mechanisms at once, making resistance far less likely to evolve.26PubMed Central. Maxamycins: Durable Antibiotics Derived by Rational Redesign of Vancomycin These compounds remain in preclinical stages, but they represent one of the more creative strategies in the fight against antimicrobial resistance: taking a drug bacteria already know how to beat and engineering it so the old tricks no longer work.
Supply Chain Vulnerabilities
One underappreciated risk with glycopeptide antibiotics is supply reliability. Antimicrobial shortages are a recognized global health security concern, and the economic consequences of losing access to even a single essential antibiotic can run into tens of millions of euros.27BMJ Journals (Shortage of essential antimicrobials: a major challenge to global health security). Shortage of essential antimicrobials: a major challenge to global health security Vancomycin is one of relatively few drugs that can treat serious MRSA infections, so a manufacturing disruption or raw-material shortage would leave hospitals with very limited alternatives. This is compounded by the fact that many glycopeptide antibiotics are derived from natural products fermented by soil-dwelling Actinomycetes bacteria, a production process that is less easily scaled up or switched between facilities than purely synthetic drug manufacturing. The fragility of these supply chains is an argument for maintaining and developing multiple glycopeptide options, including teicoplanin and the newer lipoglycopeptides, rather than depending entirely on vancomycin.